Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

Inmune Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
01/13/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Fact Sheet",
"INmune Slide Presentation"
01/09/2020 3 ALLEN MARCIA (Director) has filed a Form 3 on Inmune Bio, Inc.
01/02/2020 8-K Quarterly results
12/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INMUNE BIO PRESS RELEASE DATED DECEMBER 2, 2019"
12/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INMUNE BIO PRESS RELEASE DATED DECEMBER 2, 2019"
11/29/2019 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "INmune Bio’ s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’ s drug development."
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Granted 300,000 options @ $3.91, valued at $1.2M
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/27/2019 4 Baracchini Edgardo Jr (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Granted 108,000 options @ $3.91, valued at $422.3k
11/20/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
11/08/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/21/2019 8-K Quarterly results
10/08/2019 8-K Quarterly results
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Session 3: Therapeutics: State of the Field Presentation Title: A Biomarker-Directed Approach to Targeting Inflammation in Alzheimer’ s Patients Time and Date: 5:10 PM – 5:30 PM, Sept. 25 Location: Hyatt Regency Sydney, Australia"
09/18/2019 8-K Quarterly results
09/12/2019 4 Lowdell Mark William (Chief Scientific Officer) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,918 shares @ $6.2298, valued at $18.2k
09/12/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
09/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference"
08/27/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Investor Fact Sheet"
08/22/2019 4 Juda Scott (Director) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 2,500 shares @ $6, valued at $15k
Bought 2,500 shares @ $6, valued at $15k
08/21/2019 4 Moss David J (CFO, Treasurer & Secretary) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 77 shares @ $5.65, valued at $435.1
Bought 239 shares @ $5.65, valued at $1.4k
Bought 2,000 shares @ $5.65, valued at $11.3k
Bought 72 shares @ $5.65, valued at $406.8
Bought 236 shares @ $5.65, valued at $1.3k
Bought 376 shares @ $5.65, valued at $2.1k
08/21/2019 4 Tesi Raymond Joseph (President & CEO) has filed a Form 4 on Inmune Bio, Inc.
Txns: Bought 100 shares @ $5.96, valued at $596
Bought 100 shares @ $5.9239, valued at $592.4
Bought 1,000 shares @ $6.0308, valued at $6k
08/16/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
08/15/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
08/12/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/09/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy